Xenetic Biosciences, Inc. (XBIO) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Xenetic Biosciences, Inc. (NASDAQ:XBIO) released its earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03), Bloomberg Earnings reports.

Shares of Xenetic Biosciences (NASDAQ:XBIO) traded up $0.08 during midday trading on Thursday, reaching $2.18. The company’s stock had a trading volume of 28,400 shares, compared to its average volume of 17,208. Xenetic Biosciences has a 1-year low of $1.75 and a 1-year high of $5.90.

TRADEMARK VIOLATION WARNING: This story was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://transcriptdaily.com/2017/11/16/xenetic-biosciences-inc-xbio-releases-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.

Separately, Zacks Investment Research raised Xenetic Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Saturday, September 9th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply